Endo International: Q1 Earnings Insights

Shares of Endo International ENDP rose 1.1% after the company reported Q1 results.

Quarterly Results

Earnings per share were up 79.25% year over year to $0.95, which beat the estimate of $0.53.

Revenue of $820,405,000 higher by 13.88% from the same period last year, which beat the estimate of $707,650,000.

Guidance

Endo International hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: May 07, 2020

Time: 05:02 PM ET

Webcast URL: https://edge.media-server.com/mmc/p/kk3vi2nq

Technicals

Company's 52-week high was at $8.55

52-week low: $1.97

Price action over last quarter: down 20.07%

Company Overview

After a string of acquisitions and divestitures, Endo is a specialty pharmaceutical company with a considerable presence in pain management. The acquisitions of Auxilium and Par increased the company's presence in urology and generics, respectively.